An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STX209 (Arbaclofen) in Subjects With Autism Spectrum Disorders
Latest Information Update: 02 Aug 2013
At a glance
- Drugs Arbaclofen (Primary)
- Indications Pervasive child development disorders
- Focus Adverse reactions
- 01 Jul 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 06 Nov 2012 New trial record